MPLN News


New Guideline Advances Standardization of EGFR Mutation and ALK-Rearrangement Testing in Lung Cancer

Posted on November 20 2014 by J Seabrook

New guidance, endorsed by ASCO, outlines patient selection criteria for treatment of advanced-stage lung adenocarcinoma or tumors with an adenocarcinoma component with EGFR or ALK inhibitors based on EFGR mutation and ALK rearrangement. The guideline…
Read more


Illumina.jpg

MPLN ACQUIRES THE FIRST FDA APPROVED HIGH THROUGHPUT DNA SEQUENCING ANALYZER

Posted on October 03 2014 by Jonathan Mulkey

Molecular Pathology Laboratory Network, Inc. (MPLN) acquires the Illumina MiSeqDx™ next generation sequencing system to expand its portfolio of molecular testing and clinical research services to support growing demand in personalized medicine.


Read more

Billing & Coding Update

Posted on June 04 2014 by Jonathan Mulkey

CMS is now requiring two new HCPCS codes be billed when performing immunohistochemistry stains. G0461, for the first antibody stain, and G0462 for each additional stain are the two codes replacing 88342.

MPLN is now billing G-codes (G0461…
Read more


Behind the Scenes at MPLN

Posted on June 04 2014 by Jonathan Mulkey

Pathology residents from the University of Tennessee in Knoxville (UT) and the East Tennessee State University (ETSU) Quillen College of Medicine in Johnson City, are familiar sights in the laboratories of MPLN. A partnership began with UT and MPLN…
Read more


MPLN’s Dr. Potter Presents to the FDA

Posted on June 04 2014 by Jonathan Mulkey

On March 26th, MPLN’s Chief Scientific Officer and Director of Molecular Diagnostics,…
Read more


2 3 4 5 6 7 8